Both companies have agreed to work to prevent any disruption of supply to existing purchasers of generics from Actavis. In addition, Actavis has committed to continue to supply the Australian market with its generics until the transition is completed. The subsidiary lists more than 100 prescription generics on its website.

Actavis will also continue to supply its brand-name medications to the Australian market. Actavis products sold in Australia include osteoporosis treatment Actonel (risedronate) and a transdermal patch to treat overactive bladder Oxytrol (oxybutynin).

The sale of its Australian generics business marks another step by Actavis to distinguish itself as a brand-name medicines provider. Following the acquisition of Botox-maker Allergan by Actavis in November 2014 [1] the company stated its intention to adopt ‘Allergan’ as its corporate name. The company will, however, keep the Actavis name it says ‘for select geographic regions and product portfolios’ [2].

Related article
Actavis to buy UK generics maker Auden McKenzie

References
1.   GaBI Online - Generics and Biosimilars Initiative. Actavis buys Allergan and joins pharma top 10 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 15]. Available from: www.gabionline.net/Pharma-News/Actavis-buys-Allergan-and-joins-pharma-top-10 

2.   GaBI Online - Generics and Biosimilars Initiative. Actavis receives generic opioid approval and plans name change [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 15]. Available from: www.gabionline.net/Generics/News/Actavis-receives-generic-opioid-approval-and-plans-name-change

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.